Meeting
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
Authors
Sudhir Manda
Arizona Oncology, The US Oncology Network, Tucson, AZ
Sudhir Manda , Bertrand Marquess Anz III, Christopher Benton , E. Randolph Broun , Habte Aragaw Yimer , Jason M. Melear , Jose C. Cruz , Suzanne Fanning , Jeff Porter Sharman , Kingston Kang , Anders Svensson , Madhavi Pai , George F. Geils , John Scott Renshaw , William Bruce Donnellan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03941964
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7044)
DOI
10.1200/JCO.2022.40.16_suppl.7044
Abstract #
7044
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
First Author: Shaji Kumar
Poster
2022 ASCO Annual Meeting
Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
First Author: Farhad Ravandi
Poster
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
First Author: Curtis Andrew Lachowiez
Poster
2020 ASCO Virtual Scientific Program
Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.
First Author: Abhishek Maiti